
FIGURE 1.
Patients' flow diagram. Out of 123 patients, 58 (47.1%) with primary localized retrperitoneal sarcomas (RPS) were included in the study and 65 were excluded. 34 (27.6%) were excluded as they presented as primary metastatic cases (6), locally recurrent cases (14) or cases with residual disease after operation elsewhere (14), and 31 patients (25.2%) were excluded as they had CT performed > 30 days from initial assessment or CT image was not technically adequate for analysis
TABLE 1.
Clinical characteristics of study population
| Clinical characteristic (N = 58) | Median (IQR); n (%) |
|---|---|
| Age, years | 61.0 (46.0 – 67.0) |
| Gender | |
| Male | 34 (58.6%) |
| Female | 24 (41.4%) |
| ASA grade | |
| 1 | 9 (16%) |
| 2 | 30 (52%) |
| 3 | 16 (28%) |
| 4 | 3 (5.2%) |
| Baseline albumin, g/L | 41.0 (34.2 – 45.0) |
| Baseline C-reactive protein, mg/L | 13.5 (2.0 – 66.5) |
| Neutrophil-lymphocyte ratio | 3.3 (2.1 – 4.7) |
| Body Mass Index, kg/m2 | 26.0 (24.7 – 29.7) |
| Nutrition and body composition characteristics | |
| Nutritional team support before operation | 28(48.3%) |
| Skeletal Muscle Area, cm2 | 45.5 (115.9 – 170.1) |
| Visceral Fat Area, cm2 | 104.5 (53.6 – 168.7) |
| Subcutaneous Adipose Tissue Area, cm2 | 167.9 (127.9 – 231.6) |
| Total Fat Area, cm2 | 23.6 (19.8 – 29.1) |
| Total Body Fat, % | 30.6 (26.8 – 32.4) |
| Lean Body Mass, kg | 52.7 (50.0 – 57.2) |
| Skeletal Muscle Index, cm2/m2 | 50.2 (44.0 – 55.6) |
| Appendicular Skeletal Muscle Index, cm2/m2 | 6.70 (6.00 – 7.3) |
| Myopenia based on estimated cut-off value for SMIa | 18 (31.0%) |
| Myopenia based on EWGSOP2 criteria for SMI | 19 (32.8%) |
| Cancer cachexia | 13 (22.4%) |
| Visceral obesity | 21 (36.2%) |
| Myopenic obesity | 4 (6.9%) |
| Myosteatosisa | 37 (63.7%) |
| Pathologic characteristics and postoperative outcome data | |
| Postoperative (90 day) complication rate | 37 (64%) |
| Abdominal complication | 24 (41%) |
| Systemic complication | 17 (29%) |
| Abdominal and systemic complications | 5 (9.0%) |
| Clavien-Dindo > IIIa | |
| Yes | 17 (29%) |
| No | 41 (71%) |
| Comprehensive Complication Index | 20.92 (0.0–32.55) |
| Histologic type | |
| Liposarcoma | 35 (60%) |
| Leiomyosarcoma | 9 (16%) |
| Pleomorphic sarcoma | 1 (1.7%) |
| Other | 13 (22%) |
| Tumour size, cm | 20 (11–30) |
| FNCLCC grade | |
| 1 | 15 (26%) |
| 2 | 11 (19%) |
| 3 | 23 (40%) |
| Unknown | 9 (16%) |
| Stage AJCC (8th edition) | |
| 1A | 1 (1.7%) |
| 1B | 23 (40%) |
| 3A | 6 (10%) |
| 3B | 28 (48%) |
| Completeness of surgical resection | |
| R0 | 47 (81%) |
| R1/R2 | 11 (19%) |
AJCC = The American Joint Committee on Cancer; ASA = American Society of Anesthesiologists classification; EWGSOP2 = The European Working Group on Sarcopenia in Older People; FNCLCC = Fédération Nationale des Centres de Lutte Contre Le Cancer
Summary for continuous variables is presented as median (interquartile range) and the statistical test is Kruskal-Wallis/Mann-Whitney;
a cut-off values displayed in Table 3
TABLE 2.
Comparison of clinical and body composition parameters between myopenic and non-myopenic patients (EGSWOP2 criteria)
| Clinicopathological factor | Levela | Myopenicb | Non Myopenicb | p |
|---|---|---|---|---|
| Age, years | Median (IQR) | 66.0 (50.5–71.5) | 61.0 (46.0–64.8) | 0.236 |
| Gender | Male | 11(57.9) | 23 (60.5) | 1 |
| Female | 8(42.1) | 15 (39.5) | ||
| ASA Grade, 2–3 vs. 1 | 1 | 3 (15.8) | 6 (15.8) | 1 |
| 2–3 | 16 (84.2) | 32 84.2) | ||
| FNCLCC Grade | 1 | 5 (29.4) | 10 (32.3) | 0.547 |
| 2 | 5 (29.4) | 5 (16.1) | ||
| 3 | 7 (41.2) | 16 (51.6) | ||
| (Missing) | 7 (18.4) | 2 (10.5) | ||
| Tumour size, cm | Median (IQR) | 26.0 (20.5–34.0) | 17.5 (10.0–24.8) | 0.005 |
| Clavien-Dindo > IIIa | Yes | 3 (15.8) | 14 (36.8) | 0.183 |
| No | 16 (84.2) | 24 (63.2) | ||
| Neutrophil-lymphocyte ratio | Median (IQR) | 3.9 (2.4–4.7) | 3.0 (2.1–4.7) | 0.504 |
| Baseline albumin, g/L | Median (IQR) | 40.0 (32.0–42.5) | 43.0 (35.0–45.8) | 0.232 |
| Baseline C-reactive protein, mg/L | Median (IQR) | 44.0 (7.5–99.5) | 6.0 (2.0–45.0) | 0.088 |
| Haemoglobin level, g/L | Median (IQR) | 128.0 (101.5–136.5) | 132.5 (115.2–145.8) | 0.141 |
| Preoperative radiotherapy | No | 19 (100.0) | 37 (97.4) | 1 |
| Yes | 0 (0.0) | 1 (2.6) | ||
| Resection status | R0 | 17 (89.5) | 29 (76.3) | 0.406 |
| R1 | 2 (10.5) | 9 (23.7) | ||
| Intraoperative blood loss, ml | Median (IQR) | 1300.0 (425.0–4100.0) | 1350.0 (500.0–2075.0) | 0.78 |
| Stage AJCC, 8th edition | 1A–1B | 7 (36.8) | 17 (44.7) | 0.776 |
| 3A–3B | 12 (63.2) | 21 (55.3) | ||
| Histology subtype | Pleomorphic | 1 (5.3) | 0 (0.0) | 0.184 |
| Liposarcoma | 14 (73.7) | 21 (55.3) | ||
| Leiomyosarcoma | 2 (10.5) | 6 (15.8) | ||
| Other | 2 (10.5) | 11 (28.9) | ||
| Nutrition team before surgery | Yes | 12 (63.2) | 16 (42.1) | 0.223 |
| No | 7 (36.8) | 22 (57.9) | ||
| Length of hospital stay, days | Median (IQR) | 20.0 (11.0–28.8) | 15.0 (11.5–27.0) | 0.593 |
| Visceral obesity | Yes | 4 (21.1) | 16 (42.1) | 0.202 |
| No | 15 (78.9) | 22 (57.9) | ||
| Myosteatosis | Yes | 16 (84.2) | 21 (56.8) | 0.079 |
| No | 3 (15.8) | 16 (43.2) | ||
| Cancer cachexia | No | 12 (63.2) | 31 (83.8) | 0.163 |
| Yes | 7 (36.8) | 6 (16.2) | ||
| Body Mass Index, kg/m2 | Median (IQR) | 25.7 (23.3–27.2) | 26.9 (24.8–30.9) | 0.071 |
| Skeletal Muscle Area, HU | Median (IQR) | 115.8 (106.5–153.3) | 149.9 (130.6–177.1) | 0.019 |
| Skeletal Muscle Index, cm2/m2 | Median (IQR) | 41.0 (38.3–46.8) | 53.5 (46.2–58.8) | < 0.001 |
| Muscle Radiation Attenuation, HU | Median (IQR) | 35.6 (31.8–43.2) | 38.1 (29.9–42.2) | 0.959 |
| Subcutaneous Adipose Tissue Area, cm2 | Median (IQR) | 156.4 (103.2–194.4) | 185.4 (131.4–254.1) | 0.078 |
| Visceral Adipose Tissue Area, cm2 | Median (IQR) | 64.6 (38.1–131.6) | 125.5 (66.1–201.7) | 0.07 |
| Visceral-to-subcutaneous adipose tissue area ratio | Median (IQR) | 0.5 (0.2–0.9) | 0.8 (0.3–1.1) | 0.393 |
| Body fat, % | Median (IQR) | 28.3 (21.3–31.6) | 31.1 (28.1–33.3) | 0.024 |
| Lean Body Mass, kg | Median (IQR) | 52.5 (50.4–57.7) | 52.8 (49.8–56.4) | 0.684 |
| Subcutaneous Adipose Tissue Index, cm2/m2 | Median (IQR) | 46.8 (30.6–67.2) | 64.6(43.9–95.0) | 0.048 |
| Visceral Adipose Tissue Index, cm2/m2 | Median (IQR) | 20.6 (13.2–43.8) | 42.3 (24.2–63.6) | 0.025 |
a Summary for continuous variables is median (interquartile range) and the statistical test is Kruskal-Wallis/Mann-Whitney;
AJCC =The American Joint Committee on Cancer; ASA = American Society of Anesthesiologists; EGSWOP2 = The European Working Group on Sarcopenia in Older People; FNCLCC = Fédération Nationale des Centres de Lutte Contre Le Cancer; HU = Hounsfield units
TABLE 3.
Results of optimal stratification analysis for body composition parameters

FIGURE 2.
Kaplan-Meier curves for OS (A–D) and forest plots of multivariate Cox regression analysis of factors associated with OS (E) and LRFS (F). Kaplan-Meier curves for OS according to presence of: (A) myopenia based on EWGSOP2 criteria (red = myopenic, blue = non-myopenic), (B) cancer cachexia (red = cachectic, blue = non-cachectic), (C) high SATI (red = SATI above estimated cohort cut-off, blue = SATI below estimated cohort cut-off) and (D) high VSR (red = VSR > 0.26, blue = VSR < 0.26);
EWGSOP2 = The European Working Group on Sarcopenia in Older People revised criteria from 2018; SATI = Subcutaneous Adipose Tissue Index, cm2/m2; SMI = Skeletal Muscle Index; VSR = Visceral-to-subcutaneous adipose tissue area ratio; OS = Overall survival; LRFS = Local recurrence-free survival; HR = Hazard ratio; AIC = Akaike Information Criterion
TABLE 4.
Summary of univariate and multivariate analysis of association between body composition and outcome following surgery for primary RPS
| Clinicopathological factor | Length of hospital stay (> 10 days) | Clavien-Dindo > IIIa | Any complication (overall morbidity) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Uni-variable | Multi-variable | Uni-variable | Multi-variable | Uni-variable | Multi-variable | |||||||
| OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | OR (95% CI) | p | |
| Myopenia, yes vs. noa | 1.34 (0.38–5.54) | 0.664 | - | - | 0.32 (0.07–1.18) | 0.112 | - | - | 3.11 (0.85–15.08) | 0.112 | - | - |
| Visceral obesity, yes vs. no | 2.54 (0.68–12.40) | 0.196 | - | - | 0.65 (0.18–2.13) | 0.49 | - | - | 3.61 (1.09–14.44) | 0.047 | - | - |
| Myopenic obesity, yes vs. no | 0.01 (0.00–0.001) | 0.993 | - | - | 20090605.83 (0.00–NA) | 0.993 | - | - | 279.10 (0.00–NA) | 0.993 | - | - |
| Myosteatosis, yes vs. no | 1.39 (0.39–5.76) | 0.626 | - | - | 2.17 (0.58–10.58) | 0.282 | - | - | 5.05 (1.39–24.41) | 0.023 | 4.63 (1.03–28.42) | 0.063 |
| Cancer cachexia, yes vs. no | 0.68 (0.18–2.94) | 0.585 | - | - | 2.83 (0.76–10.59) | 0.117 | - | - | 0.95 (0.27–3.60) | 0.935 | - | - |
| Body mass index, kg/m2 | 1.00 (0.89–1.14) | 0.992 | - | - | 0.94 (0.81–1.06) | 0.351 | - | - | 0.95 (0.27–3.60) | 0.935 | - | - |
| Skeletal Muscle Area, HU | 1.00 (0.99–1.02) | 0.869 | - | - | 1.00 (0.98–1.01) | 0.679 | - | - | 1.00 (0.99–1.02) | 0.681 | - | - |
| Skeletal Muscle Index, cm2/m2 | 1.00 (0.95–1.07) | 0.88 | - | - | 1.00 (0.95–1.06) | 0.909 | - | - | 1.04 (0.98–1.10) | 0.230 | - | - |
| Muscle Radiation Attenuation, HU | 0.98 (0.92–1.04) | 0.526 | - | - | 0.99 (0.93–1.05) | 0.775 | - | - | 0.94 (0.88–1.00) | 0.076 | - | - |
| SAT, cm2 | 1.00 (0.99–1.00) | 0.336 | - | - | 1.00 (0.99–1.00) | 0.48 | - | - | 1.00 (0.99–1.01) | 0.866 | - | - |
| VAT, cm2 | 1.00 (1.00–1.01) | 0.769 | - | - | 1.00 (0.99–1.00) | 0.622 | - | - | 1.00 (1.00–1.01) | 0.205 | - | - |
| VSR | 1.55 (0.53–5.51) | 0.456 | - | - | 1.09 (0.39–2.861) | 0.861 | - | - | 1.72 (0.66–5.19) | 0.292 | - | - |
| High VSRb, yes vs. no | 2.50 (0.63–9.52) | 0.179 | - | - | 2.75 (0.63–19.26) | 0.224 | - | - | 6.19 (1.69–26.52) | 0.008 | 5.05 (1.08–29.74) | 0.05 |
| Body fat, % | 0.96 (0.87–1.05) | 0.380 | - | - | 1.00 (0.92–1.09) | 0.962 | - | - | 1.00 (0.93–1.09) | 0.912 | - | - |
| Lean Body Mass, kg | 1.01 (0.96–1.07) | 0.765 | - | - | 1.02 (0.97–1.08) | 0.381 | - | - | 1.02 (0.97–1.08) | 0.381 | - | - |
| SATI, cm2/m2 | 0.99 (0.97–1.01) | 0.279 | - | - | 0.99 (0.97–1.01) | 0.344 | - | - | 1.00 (0.99–1.02) | 0.794 | - | - |
| VATI, cm2/m2 | 1.00 (0.99–1.02) | 0.625 | - | - | 1.00 (0.98–1.01) | 0.706 | - | - | 1.01 (1.00–1.04) | 0.122 | - | - |
| High SATIc, yes vs. no | 1.80 (0.52–6.25) | 0.346 | - | - | 0.90 (0.26–2.93) | 0.863 | - | - | 1.50 (0.49–4.81) | 0.481 | - | - |
| High VATId, yes vs. no | 0.49 (0.10–1.87) | 0.327 | - | - | 0.38 (0.08–1.44) | 0.184 | - | - | 2.83 (0.84–11.45) | 0.111 | - | - |
OR = Odds Ratio; SAT = Subcutaneous Adipose Tissue Area; SATI = Subcutaneous Adipose Tissue Index; VAT = Visceral Adipose Tissue Area; VATI = Visceral Adipose Tissue Index; VSR = Visceral-to-subcutaneous adipose tissue area ratio;
Only significant variables (p < 0.05) were included in multivariate analysis.

FIGURE 3.
Association between overall morbidity following surgery for primary RPS and body composition (A–F) and linear correlation analysis between VSR and VATI (G) and VSR and fat mass (H). VSR (F) and intraoperative blood loss (E) independently predicted worse postoperative outcome. In multivariate analysis skeletal muscle index (SMA), lean body mass (LBM), subcutaneous adipose tissue area (SAT) and visceral adipose tissue area (VAT) were not associated with statistically higher overall postoperative morbidity (A–D).
VATI = Visceral Adipose Tissue Index; VSR = Visceral-to-subcutaneous adipose tissue area ratio. ȓPearson = Pearson Correlation Coefficient; tStudent = result of t-test for correlation